Ryann Grochowski Jones was the data editor at ProPublica. Previously, she was a data reporter at ProPublica and at Investigative Newsource/KPBS in San Diego, California. She received her master’s degree from the University of Missouri School of Journalism, where she was a data librarian for Investigative Reporters and Editors/National Institute for Computer-Assisted Reporting. Ryann started her career as a municipal beat reporter for her hometown newspaper in Wilkes-Barre, Pennsylvania.
Ryann Grochowski Jones
Data Editor
What Percentage of Doctors at Your Hospital Take Drug, Device Payments?
Where a hospital is located makes a big difference in how many of its doctors take payments from drug and medical device companies. See how your state compares and look up your hospital.
Another Study Finds Link Between Pharma Money and Brand-name Prescribing
The findings, by researchers at Harvard Medical School, are in line with a similar analysis done by ProPublica in March.
Now There’s Proof: Docs Who Get Company Cash Tend to Prescribe More Brand-Name Meds
The more money doctors receive from drug and medical device companies, the more brand-name drugs they tend to prescribe, a new ProPublica analysis shows. Even a meal can make a difference.
Updated Dollars for Docs
This release includes updated data, payments to teaching hospitals, and information about brand-name prescribing rates for some doctors.
Treatment Tracker
We've updated our database of Medicare’s payments to individual doctors and other health professionals serving the 49 million seniors and disabled in its Part B program.
Treatment Tracker Methodology
How we made a news app to compare doctors Medicare billing patterns.
New Dollars for Docs
Pharmaceutical and medical device companies paid billions to doctors from late 2013 through 2014, new data shows. Search for your doctor in our interactive database.
A Pharma Payment A Day Keeps Docs' Finances Okay
New data on payments from drug and device companies to doctors show that many doctors received payments on 100 or more days last year. Some received payments on more days than they didn't.
About the Dollars for Docs Data
Details behind our drug company money database.
One Nation, Under Sedation: Medicare Paid for Nearly 40 Million Tranquilizer Prescriptions in 2013
Congress wouldn’t allow Medicare to pay for benzodiazepines such as Xanax and Ativan until 2013. Now, the medications are among the most prescribed in its drug program.
Money as a Weapons System
How U.S. commanders spent $2 billion of petty cash in Afghanistan
One Year, 2,000+ Downloads: Here’s How Our Data Store Is Doing
A year after we launched it, here’s what our Data Store looks like.
Uber Claims Credit for Drop in Drunk Driving Accidents. But Where's the Evidence?
The ridesharing service published a report last week with Mothers Against Drunk Driving connecting the rise of Uber to a drop in drunk driving accidents. Except the connection isn't so clear.
Why Pharma Payments to Doctors Were So Hard to Parse
Flaws in information submitted to Open Payments, a government database of financial relationships in the medical field, complicated our analysis.
Vying for Market Share, Companies Heavily Promote 'Me Too' Drugs
Our comprehensive analysis of drug company spending on doctors in the last five months of 2013 shows the most-promoted products typically were not cures, breakthroughs or top sellers.
Open Payments Explorer: How Much Industry Money Goes to Doctors and Teaching Hospitals
Beginning in 2014, the federal government mandated that pharmaceutical and medical device manufacturers publicly report payments made to doctors and teaching hospitals. The first report covered the last five months of 2013. Use this tool to search for a company, drug or device — and compare it to another.
Methodology for Calculating Company Payments to Doctors
Even with new federal data, it's not easy to track drug, device company spending on their products
Answering the Critics of our Deadly Force Story
We respond to arguments levied against our analysis of justified homicides by police officers.
As Controlled Substance Use Rises in Medicare, Prolific Prescribers Face More Scrutiny
Despite warnings about abuse, Medicare covered more prescriptions for potent controlled substances in 2012 than it did in 2011. The program's top prescribers often have faced disciplinary action or criminal charges related to their medical practices.